Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma
Background
Neutralizing-antibody (nAb) is the major focus of most ongoing COVID-19 vaccine trials. However, nAb response against SARS-CoV-2, when present, decays rapidly. Given the myriad roles of antibodies in immune responses, it is possible that antibodies could also mediate protection against SARS-CoV-2 via effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), which we sought to explore here.
Methods
Plasma of 3 uninfected controls and 20 subjects exposed to, or recovering from, SARS-CoV-2 infection were collected from U.S. and sub-Saharan Africa. Immunofluorescence assay was used to detect the presence of SARS-CoV-2 specific IgG antibodies in the plasma samples. SARS-CoV-2 specific neutralizing capability of these plasmas was assessed with SARS-CoV-2 spike pseudotyped virus. ADCC activity was assessed with a calcein release assay.
Results
SARS-CoV-2 specific IgG antibodies were detected in all COVID-19 subjects studied. All but three COVID-19 subjects contained nAb at high potency (>80% neutralization). Plasma from 19/20 of COVID-19 subjects also demonstrated strong ADCC activity against SARS-CoV-2 spike glycoprotein, including two individuals without nAb against SARS-CoV-2.
Conclusion
Both neutralizing and non-neutralizing COVID-19 plasmas can mediate ADCC. Our findings argue that evaluation of potential vaccines against SARS-CoV-2 should include investigation of the magnitude and durability of ADCC, in addition to nAb.
Top-30
Citations by journals
1
2
3
4
5
6
|
|
Frontiers in Immunology
6 publications, 11.32%
|
|
Journal of Medical Virology
3 publications, 5.66%
|
|
Signal Transduction and Targeted Therapy
2 publications, 3.77%
|
|
Scientific Reports
2 publications, 3.77%
|
|
Cell Reports
2 publications, 3.77%
|
|
Journal of Infectious Diseases
2 publications, 3.77%
|
|
Vaccines
2 publications, 3.77%
|
|
JCI insight
1 publication, 1.89%
|
|
Reviews in Medical Virology
1 publication, 1.89%
|
|
Medicina
1 publication, 1.89%
|
|
Nature
1 publication, 1.89%
|
|
JAAD Case Reports
1 publication, 1.89%
|
|
Immunity
1 publication, 1.89%
|
|
Journal of Virological Methods
1 publication, 1.89%
|
|
Genetics in Medicine
1 publication, 1.89%
|
|
Transfusion Medicine Reviews
1 publication, 1.89%
|
|
EBioMedicine
1 publication, 1.89%
|
|
Cell Reports Medicine
1 publication, 1.89%
|
|
Journal of Immunological Methods
1 publication, 1.89%
|
|
Cytometry. Part A : the journal of the International Society for Analytical Cytology
1 publication, 1.89%
|
|
Immunological Reviews
1 publication, 1.89%
|
|
Journal of Biomolecular Structure and Dynamics
1 publication, 1.89%
|
|
Science immunology
1 publication, 1.89%
|
|
Emerging Microbes and Infections
1 publication, 1.89%
|
|
Life Sciences
1 publication, 1.89%
|
|
Pathogens
1 publication, 1.89%
|
|
Plant Biotechnology Journal
1 publication, 1.89%
|
|
Antiviral Research
1 publication, 1.89%
|
|
Frontiers of Medicine
1 publication, 1.89%
|
|
1
2
3
4
5
6
|
Citations by publishers
2
4
6
8
10
12
|
|
Elsevier
12 publications, 22.64%
|
|
Wiley
7 publications, 13.21%
|
|
Springer Nature
7 publications, 13.21%
|
|
Frontiers Media S.A.
6 publications, 11.32%
|
|
Cold Spring Harbor Laboratory
6 publications, 11.32%
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
5 publications, 9.43%
|
|
Oxford University Press
2 publications, 3.77%
|
|
American Society for Clinical Investigation
1 publication, 1.89%
|
|
Taylor & Francis
1 publication, 1.89%
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 1.89%
|
|
Higher Education Press
1 publication, 1.89%
|
|
Bentham Science
1 publication, 1.89%
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 1.89%
|
|
2
4
6
8
10
12
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.